ATEX.NASDAQAnterix INC

Form 4: Anterix Inc. Executive Granted Stock Options

Sentiment:

SEC Form 4 Filing


Anterix Inc.'s Chief Operating Officer, Ryan Gerbrandt, was granted stock options for 67,774 shares, vesting over three years starting January 16, 2025.

Summary

  • Ryan Gerbrandt, the Chief Operating Officer of Anterix Inc., was granted stock options to purchase 67,774 shares of common stock.
  • The options have an exercise price of $27.83 per share.
  • The options vest in three equal annual installments, beginning on January 16, 2025.
  • The options expire on January 16, 2035.
  • The vesting is contingent upon Mr. Gerbrandt's continued employment with Anterix.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

  • The stock option grant aligns the executive's interests with those of the shareholders.
  • The vesting schedule encourages long-term commitment from the executive.

Risks

  • The value of the options is dependent on the future performance of Anterix's stock price.
  • The executive must remain employed with the company to fully vest the options.

Future Outlook

The executive's future compensation is tied to the company's stock performance through these options.

Industry Context

Stock options are a common form of executive compensation in the technology and telecommunications industries, used to incentivize performance and retain key talent.

Comparison to Industry Standards

  • Stock option grants are a standard practice for executive compensation across many industries, particularly in technology and growth-oriented companies.
  • The vesting schedule of three years is also a common practice to ensure long-term commitment from executives.
  • The specific number of options and exercise price would need to be compared to similar companies to assess if it is in line with industry standards.

Stakeholder Impact

  • Shareholders may view this positively as it incentivizes the executive to improve company performance.
  • Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

DateDescription
01/16/2025Date of the stock option grant and the start of the vesting period.
01/16/2035Expiration date of the stock options.
01/21/2025Date the form was signed by the Attorney-in-Fact.

Keywords

stock options, executive compensation, vesting, Anterix Inc., Ryan Gerbrandt, equity

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.